Iaso Therapeutics, Inc.
Iaso Therapeutics is dedicated to developing next generation vaccines to enhance human health and treat diseases. It focuses on innovative vaccine technologies, including a proprietary mutant bacteriophage Qβ platform, to address infectious diseases and cancer. The company aims to translate cutting-edge research into real-world health solutions, leveraging collaborations with Michigan State University and support from various grants and investments.
Industries
Nr. of Employees
small (1-50)
Iaso Therapeutics, Inc.
4942 Dawn Avenue, Suite 150, East Lansing, MI 48823
Products
Mutant bacteriophage Qβ virus-like particle (VLP) carrier platform
A VLP-based carrier platform engineered to enhance antibody responses when conjugated to subunit antigens; intended for use in conjugate vaccine development.
Mutant bacteriophage Qβ virus-like particle (VLP) carrier platform
A VLP-based carrier platform engineered to enhance antibody responses when conjugated to subunit antigens; intended for use in conjugate vaccine development.
Services
Collaborative development agreements and sublicenses to leverage the VLP carrier platform in partner vaccine programs.
Design and execution of preclinical studies including antigen conjugation, formulation, animal immunizations, and antibody readouts to assess vaccine candidates.
Collaborative development agreements and sublicenses to leverage the VLP carrier platform in partner vaccine programs.
Design and execution of preclinical studies including antigen conjugation, formulation, animal immunizations, and antibody readouts to assess vaccine candidates.
Expertise Areas
- Next-generation vaccine platform development
- Conjugate vaccine chemistry
- Glyco-chemistry and complex glycan synthesis
- Preclinical immunology and animal models
Key Technologies
- Virus-like particle (VLP) platforms
- Conjugate antigen chemistry
- Complex glycan synthesis
- Nanoparticle vaccine delivery
News & Updates
East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in an annual class project with the MSU Finance 444 class taught by Associate Professor Zsuzsanna Fluck, the Director of the Center for Venture Capital, Private Equity, and Entrepreneurial Finance in the Eli Broad College of Business at MSU. MSU SVCF gives students the opportunity to learn what it is like to be in the venture capital space. The students complete thorough due diligence on participating companies and the top five startups are recommended for funding through Red Cedar Ventures. This is the third year the MSU SVCF has partnered with Red Cedar Ventures to make investments in Michigan-based start-ups.
Crain’s Detroit covers Iaso Therapeutics. The interview reports on the history and funding of Iaso.
Iaso Therapeutics announced the first close of its $1.25 million Series Seed Preferred round of financing, supporting the development of its vaccine platform based on bacteriophage mQβ.
East Lansing, MI – Iaso has been selected to receive a $10k investment by the Michigan State University (MSU) Student Venture Capital Fund (MSU SVCF). This spring, Iaso participated in an annual class project with the MSU Finance 444 class taught by Associate Professor Zsuzsanna Fluck, the Director of the Center for Venture Capital, Private Equity, and Entrepreneurial Finance in the Eli Broad College of Business at MSU. MSU SVCF gives students the opportunity to learn what it is like to be in the venture capital space. The students complete thorough due diligence on participating companies and the top five startups are recommended for funding through Red Cedar Ventures. This is the third year the MSU SVCF has partnered with Red Cedar Ventures to make investments in Michigan-based start-ups.
Crain’s Detroit covers Iaso Therapeutics. The interview reports on the history and funding of Iaso.
Iaso Therapeutics announced the first close of its $1.25 million Series Seed Preferred round of financing, supporting the development of its vaccine platform based on bacteriophage mQβ.